BioSpace News Archive

Berkshire Biomedical Corporation announced today that the company issued $2.75 million in 8% convertible promissory notes (the “Notes”) to a group of qualified investors, including founding and other investors who participated in the previous capital raise.

Castle Biosciences, Inc. today announced recent poster presentations on the Company’s suite of dermatologic cancer gene expression profile (GEP) tests, as well as a poster describing the study design for its inflammatory skin disease pipeline initiative at the 2021 Fall Clinical Dermatology Conference, held Oct. 21-24.

RaySearch Laboratories AB (publ) and Mevion Medical Systems , two companies that are leading the field of proton therapy, announce a collaboration to develop advanced treatment planning techniques for FLASH delivery with the MEVION S250i Proton Therapy System.

Generation Bio Co. today presented new preclinical data demonstrating widespread delivery of multiple nucleic acid cargos to photoreceptors using the company’s cell-targeted lipid nanoparticle (ctLNP).

Achilles Therapeutics plc today delivered an oral presentation (OR54) at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress.

ASRS Top 10 awarded to Palatin’s pre-clinical diabetic retinopathy poster demonstrating positive effects of melanocortin agonists for retinal inflammation

Nutriband Inc. is pleased to announce the receipt of $2,062,500 in additional gross from the exercise of warrants issued in the Company’s October 1, 2021 public offering of securities.

-- Study uses Invitae Personalized Cancer Monitoring (PCM™) liquid biopsy to accurately profile tumors and enhance cancer circulating tumor DNA-based minimal residual disease (MRD) lead times; highlights promise for personalized cancer care --

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will establish a new site focusing on Translational Medicine and Formulation Research in San Diego.

Semler Scientific, Inc. today announced that it will report financial results for the third quarter and first nine months ended September 30, 2021